Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Hormone Therapy Class Labeling Uses Wyeth Template; Appeals Due By March

Executive Summary

Sponsors of hormone replacement therapies have two months to pull together data to justify exemptions to FDA's proposed class labeling incorporating risk information from the Women's Health Initiative

You may also be interested in...



Premarin WHI Results May Mean Additional Labeling Changes, FDA Says

FDA may request additional changes to the labeling of hormone replacement therapies based on the findings from the terminated Premarin arm of the Women's Health Initiative

Premarin WHI Results May Mean Additional Labeling Changes, FDA Says

FDA may request additional changes to the labeling of hormone replacement therapies based on the findings from the terminated Premarin arm of the Women's Health Initiative

Berlex Climara Pro Triglyceride Effect Is Point Of Difference For HRT Patch

Berlex Labs can highlight Climara Pro's effect on triglycerides as one point of differentiation in marketing the transdermal hormone therapy product

Related Content

UsernamePublicRestriction

Register

PS041088

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel